A practical review on carfilzomib in multiple myeloma

Eli Muchtar, Morie A. Gertz, Hila Magen

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high-risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.

Original languageEnglish (US)
Pages (from-to)564-577
Number of pages14
JournalEuropean Journal of Haematology
Issue number6
StatePublished - Jun 1 2016


  • Carfilzomib
  • Combination regimen
  • Induction
  • Multiple myeloma
  • Proteasome inhibitors
  • Relapse

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'A practical review on carfilzomib in multiple myeloma'. Together they form a unique fingerprint.

Cite this